| Name | Title | Contact Details |
|---|
RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. From home to hospital and ER to OR, RapidAI is leading the next evolution of clinical decision-making and patient workflow, bringing the end-to-end patient journey into focus. Based on intelligence gained from over 4 million scans in more than 2000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible, saving lives, time and money.
Senior Care Services is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Mobility, Inc. is a Goodlettsville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medpricer empowers industry-leading sourcing teams To help you with the continued pressure to optimize healthcare costs, our expert team and best-in-class technology triples your internal sourcing capacity and helps you cut purchased services expenses by an average of 24% without costing you a dime. You lead – We empower You retain the control of your goals and decisions. With the Medpricer methodology and $2.7 billion of Purchased Services sourcing experience, you extend your sourcing capability upfront and establish a best-in-class infrastructure to drive ongoing success in the future. Process more than you ever imagined We discover and optimize every Purchased Service category in your organization. Built on a time-tested methodology, our industry-leading custom contracting platform helps organizations consolidate spend data and manage negotiations more. Your GPO can`t help you like we can We give your team the expertise and flexibility of a consultant with the scalability of a GPO. Access our vendor-paid, independent custom contracting system to secure the right terms at the right price for all of your 400+ Purchased Service categories.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.